These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 37451609)

  • 1. Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry.
    Lachant D; Minkin R; Swisher J; Mogri M; Zolty R; Hwang S; Seaman S; Broderick M; Sahay S
    Pulm Pharmacol Ther; 2023 Oct; 82():102232. PubMed ID: 37451609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
    Papademetriou E; Liu X; Beaudet A; Tsang Y; Potluri R; Panjabi S
    J Med Econ; 2023; 26(1):644-655. PubMed ID: 37086091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
    Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
    Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different efficacy of inhaled and oral medications in pulmonary hypertension.
    AbuHalimeh BJ; Parambil JG; Tonelli AR
    Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry).
    McLaughlin V; Farber HW; Highland KB; Hemnes AR; Chakinala MM; Chin KM; Han M; Cho M; Tobore T; Rahman M; Kim NH
    J Heart Lung Transplant; 2024 Feb; 43(2):272-283. PubMed ID: 37778526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
    Fanous SM; Janmohamed M
    Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus.
    Brewer J; Wilson M; Coons JC; Schmit A; Whittenhall ME; Kimber A; Broderick M; Lee D; Patzlaff N; Miller C; Ataya A; LaRoy V; King CS; Ravichandran AK; Kingrey JF; Sahay S
    Respir Med; 2024 Sep; 231():107734. PubMed ID: 38986791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report.
    Alexandre A; Furtado I; Carvalho L; Gonçalves F; Melo A; Alves J; Santos M; Reis A
    ESC Heart Fail; 2023 Aug; 10(4):2722-2727. PubMed ID: 37336527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis.
    Manzi G; Mariani MV; Filomena D; Recchioni T; Papa S; Scoccia G; Badagliacca R; Vizza CD
    Vascul Pharmacol; 2024 Mar; 154():107280. PubMed ID: 38309551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.
    Song C; Kunovszki P; Beaudet A
    J Health Econ Outcomes Res; 2022; 9(1):151-160. PubMed ID: 35800882
    [No Abstract]   [Full Text] [Related]  

  • 12. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
    Ackerbauer KA; Tandon R
    J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
    El Yafawi R; Wirth JA
    Curr Hypertens Rep; 2017 Oct; 19(12):97. PubMed ID: 29071454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
    Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M;
    J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil.
    Miller CE; Franco V; Smith JS; Balasubramanian V; Kingrey J; Zolty R; Melendres-Groves L; Huston J; Elwing JM; Ravichandran A; Cella D; Shen E; Seaman S; Thrasher CM; Broderick M; Oudiz RJ
    Respir Med; 2023 Nov; 218():107374. PubMed ID: 37532157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension.
    Pan IZ; Carey JR; Jacobs JA; Dechand J; Sessions JJ; Sorensen T; Penn BA; Mayeux JD; Hatton ND; Ryan JJ
    Front Med (Lausanne); 2020; 7():81. PubMed ID: 32296704
    [No Abstract]   [Full Text] [Related]  

  • 17. Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
    Thurber KM; Williams BM; Bates RE; Frantz RP
    Pharmacotherapy; 2017 Aug; 37(8):e76-e81. PubMed ID: 28513869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy.
    Adachi S; Nishiyama I; Yasuda K; Yoshida M; Nakano Y; Kondo T; Murohara T
    J Cardiol Cases; 2022 Jul; 26(1):42-45. PubMed ID: 35923524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.